Business Context and Reporting Period
Armata Pharmaceuticals, Inc. (ARMP) filed a Form 8-K on July 20, 2026, to disclose significant operational and clinical developments. The company is an emerging growth company incorporated in Washington, with principal executive offices in Los Angeles, California.
Key Financial Metrics and Funding
- Government Award: Received a $2.5 million award from the U.S. Department of Defense (DoD) announced on June 23, 2026.
- Cumulative Funding: Total funding received to date under the specific DoD award is $28.7 million.
- Revenue and Profit: The filing text does not provide a clear value for revenue, profit, cash flow, or margins.
- Debt and Liquidity: The filing text does not provide a clear value for debt levels or liquidity positions.
Material Changes and Operational Progress
- Clinical Advancement: Reported significant progress supporting the advancement of AP-SA02, an intravenously administered multi-phage product candidate for S. aureus.
- Study Plans: Progress supports a planned Phase 3 superiority study for the adjunct treatment of complicated bacteremia caused by MSSA or MRSA.
- Management Change: David House was promoted to Chief Financial Officer.
Outlook, Risks, and Contingencies
- Future Funding: The company is in close communication with DoD partners regarding potential new support for the execution of the planned Phase 3 study.
- Alternative Pathways: Separate from existing or potential DoD awards, the company continues to pursue and evaluate other funding pathways to support the Phase 3 clinical study.
- Regulatory Status: The information provided is furnished under Regulation FD and is not deemed "filed" for Section 18 liability purposes.
Investor Verification Checklist
- Verify the specific terms and milestones associated with the $2.5 million DoD award.
- Confirm the timeline and design details of the planned Phase 3 superiority study for AP-SA02.
- Assess the company's current cash runway and the status of alternative funding discussions.
- Review the full text of the press release (Exhibit 99.1) for detailed clinical data not summarized in the 8-K.